📢 It has been a learning experience over the past 3 days at #ESMOTAT25 to listen to experts in the field of #phaseI #drugdevelopment
🗣️ The talks were truly insightful
✅ New and improved drugs 🎯
📊 Innovative trial designs
@myesmo.bsky.social
@viveksubbiah.bsky.social
@oncoalert.bsky.social
What a tour de force!👨⚕️ @jnkt.bsky.social is really a trailblazer in the use of AI 🤖 in oncology practice and research.
TLDR: As an oncology community, we really need to keep abreast with the rapidly evolving (improving!) developments in AI.
Large language models
LLM “agents”
etc
#ESMOTAT25
#ESMOTAT25
“Drug discovery should be a living and adaptive process, and it starts and ends with the patient in mind…”
Are we getting a return in investment with the scientific data we have generated so far? Can AI enhance this?
- Prof Bissan Al-Lazikani
@mdanderson.bsky.social
#ESMOTAT25 has 4 ‼️workshops in collaboration with #ESMOYOC
Come and join exciting speakers and thought-provoking discussions⤵️
@drjonlim.bsky.social
Thanks #ESMOTAT25 & #ESMOYOC for the kind invitation to speak alongside #TeamManchester colleague Dr André Freitas - AI/ML 👨💻 expert @cruk-mi.bsky.social.
We discussed tips & tricks + pitfalls of using (generative) AI 🤖 for paper and grant writing.
@uom-dcs.bsky.social
@mcrcnews.bsky.social
Great programme at #ESMOTAT25 co-led by #ESMOYOC team.
At today’s lunch session, we had a workshop re: basics of pharmacokinetics - especially topical in light of recent complex therapies especially in IO.
🧑🔬 Dr Shelby Barnett @newcastleuni.bsky.social
👨⚕️ Dr Tim Schutte @nkinl.bsky.social
#ESMOTAT25
Conferencing is more fun with friends! #TeamManchester 🙌
🧑⚕️ @oncocook.bsky.social
@official-uom.bsky.social
@mcrcnews.bsky.social
High-level overview & horizon-scanning re: TILs in solid ca. Exceptional collaborative efforts between Dr Elena Garralda & Dr Alena Gros @vhio.bsky.social.
Exciting next steps for TILs:
• neoAg prediction
• derive “TILs” from blood
• armouring w/ cytokines
• reduce toxicities
and more! #ESMOTAT25
The field of cell therapy in solid tumour became even hotter 🔥 after the accelerated FDA-approval of afami-cel in 2024:
www.thelancet.com/journals/lan...
Dr Victor Moreno challenges us to think why we may need TCR-T as immTAC and T cell engagers (bi-, tri-, etc) become more advanced. #ESMOTAT25
📈 With the rise of promising autologous T cell therapy products, Dr Ulrike Köhl poses the question re: if we need to really think about allogenic options.
Interesting emerging data re: engineered allogenic CAR-NK, including for solid tumours
+ non-viral gene transfer technologies.
#ESMOTAT25
🚀 Starting off is our #TeamManchester trailblazer in cell therapy, Prof #FionaThistlethwaite.
Is CAR-T a dream or reality?
Some promising data re: CAR-T:
• Claudin 6
• Claudin 18.2
• GD2
in solid tumours.
Watch out for armoured CAR-T with novel engineering!
#ESMOTAT25
@mcrcnews.bsky.social
The tides are changing! 🌊
#ESMOTAT25 hosts a full stream on ‘cell therapies in solid tumours’.
Is cell therapy ready for prime time?
• CAR-T
• NK cells
• TCR-T
• TILs ++
Finally, great story re: evolution of bispecific T cell enagager (BiTE) - Dr Martijn Lolkema @amgen.bsky.social.
A journey re:
• Blinatumomab, CD19
• Tarlatamab, DLL3
• Tebentafusp, gp100
• Xaluritamig, STEAP1
etc
To navigate current challenges, more innovative technologies emerging! 🚀 #ESMOTAT25
Harnessing antigen presentation may improve anti-cancer immunotherapy.
Dr Matteo Simonelli provides the current state-of-play of therapeutically targeting CD47 “don’t eat me” cascade.
Some interesting first-in-human data especially with bispecific Abs & also combination strategies.
#ESMOTAT25
Kicking off Day 2️⃣ of #ESMOTAT25 with a dedicated session on ‘Bispecific Abs for IO’ - covering current and emerging immune cells of interest including:
• NK cells
• gamma-delta T cells
• macrophages
• T cells
📚Very proud of our #TeamManchester Clinical Research Fellows presenting 3️⃣ posters at #ESMOTAT25!
Poster 58P - by Dr Zoulikha Zair et al, & Posters 91P + 110P - by Dr Julio Herrero et al.
📋 Check out abstracts for further details:
cslide.ctimeetingtech.com/tat2025/atte...
@mcrcnews.bsky.social
#ESMOTAT25
🔥 Starting the day with #AI tools and it's application to #science and writing grants/papers
✅ Helping in style and format
✅ Prompts very important
❌ Plagiarism, repetition, bad for searching
Great talks by @drjonlim.bsky.social Dr Freitas
#YOC @myesmo.bsky.social @vhio.bsky.social
